SCHEMBL5436153

SCHEMBL5436153

CC(=O)Oc1cccc(C(=O)Nc2ccccc2C)c1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.56
▸ HPGD P15428 4/20 0.56
▸ KDM4E B2RXH2 3/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ HTT P42858 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ NPC1 O15118 3/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ TSHR P16473 3/20 0.52
▸ TP53 P04637 1/20 0.52
▸ MAPT P10636 4/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ PKM P14618 1/20 0.49
▸ POLB P06746 2/20 0.49
▸ TOP1 P11387 2/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2700124 0.86 NPC1 (0.63) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL28652342 0.82 HSD17B10 (0.70) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL11314930 0.80 NPC1 (0.62) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL31471693 0.80 MAOB (0.57) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL14096441 0.77 ALDH1A1 (0.60) HPGDKDM4EALDH1A1LMNAMAPK1
SCHEMBL3690385 0.77 HPGD (0.77) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL13290719 0.76 NPC1 (0.68) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL742810 0.75 ACHE (0.62) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL31229899 0.75 ACHE (0.62) HSD17B10HPGDKDM4EALDH1A1LMNA
SCHEMBL4070408 0.75 RAB9A (0.59) HPGDKDM4EALDH1A1MAPK1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070111989-A1 Novel diazabicyclononene derivatives and use ACTELION PHARMACEUTICALS LTD. (CH) 2007-05-17 — — US disclosed
EP-1692133-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2006-08-23 — — EP disclosed
WO-2005054243-A1 DIAZABICYCLONONENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070111989-A1 Novel diazabicyclononene derivatives and use REN, ACE, AGTR1 HSD17B10 185/4885HPGD 1080/4885KDM4E 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback